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A two-year-old female presented with acutely altered mental status following eight days of fever and rash. She had been camping at
an Indiana campground 11 days prior to the onset of illness and was evaluated twice for her fever and rash prior to admission.
Laboratory evaluation on admission revealed thrombocytopenia, hyponatremia, and elevated transaminases. The patient
developed diffuse cerebral edema, and despite intensive care, the edema led to brain death from Rocky Mountain spotted fever
(RMSF). We present this case to highlight the importance of considering RMSF and other tick-borne illnesses in a child with
prolonged fever and rash in a nonendemic area and also the difficulty of diagnosis in early stages of disease. A detailed travel
history, evaluation of key laboratory findings (white blood count, platelet count, and transaminases), and close follow-up if rash
and fevers persist may help to improve detection of RMSF. If a tick-borne illness such as RMSF is suspected, empiric
doxycycline therapy should be started immediately, as lab confirmation may take several days and mortality increases greatly
after five days of symptoms.
1. Introduction
The incidence of spotted fever rickettsiosis, including Rocky
Mountain spotted fever (RMSF), a tick-borne illness caused
by the organism Rickettsia rickettsii, has increased markedly
during the last two decades [1, 2]. We present a case of RMSF
that sadly ended in the death of the child, to highlight (1) the
importance of considering RMSF in a febrile child with a per-
sistent and atypical rash; (2) the difficulty of early diagnosis
in areas in which RMSF is uncommon due to the overlap in
signs, symptoms, and lab findings between RMSF and com-
mon viral illnesses; (3) the clues from history, exam, and
lab findings that may increase suspicion of RMSF; and (4)
the importance of early treatment in suspected RMSF.
2. Case Presentation
A two-year-old previously healthy female developed fevers
11 days after she went on an overnight camping trip to
Greencastle, Indiana, in the month of May. One day later, a
rash developed on her chest and upper shoulders. She was
seen at an emergency department (ED) on day two of her ill-
ness and was noted to have a diffuse maculopapular rash on
the legs and trunk, with sparing of the palms, soles, and face.
Her complete metabolic profile revealed mildly elevated
transaminases with an alanine aminotransferase (ALT) of
88U/L (normal range 7-52U/L) and aspartate amino trans-
ferase (AST) of 127U/L (normal range 13-39U/L). Complete
blood count values and the remainder of the metabolic pro-
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file were within normal limits. The rash was sufficiently
unusual that a pediatric hospitalist was called to assess it,
but by the time the hospitalist arrived, the rash had resolved.
The patient was diagnosed as having a viral syndrome and
prescribed ibuprofen for fever control.
She presented to a second ED four days later (day 6 of ill-
ness) with persistent fever and rash and decreased activity.
Exam revealed fever and a diffuse fine, maculopapular rash
in an active, alert child in no apparent distress. A throat swab
was positive for group A Streptococcus antigen. She was pre-
scribed oral amoxicillin for streptococcal pharyngitis with
scarlet fever.
The child continued to have fevers and was progressively
less active. Two days later, on the eight day of her illness, she
presented to the ED at our medical center with persistent
fever, increased rash, lethargy, and inability to ambulate.
Physical exam revealed a lethargic child with a temperature
of 37.0°C, pulse of 175 beats per minute, respiratory rate of
28 breaths per minute, oxygen saturation of 90% on ambient
air, and a blood pressure of 93/55mmHg. Her exam was
notable for impaired consciousness, hypotonia, periorbital
edema, and a petechial, nonblanching rash over the all
extremities, her trunk, and her palms and soles (Figure 1).
She was intubated and admitted to the pediatric intensive
care unit. Additional history obtained from the family
revealed that she and her father had been camping near a
wooded area 11 days prior to the onset of her symptoms,
although no tick bites were observed.
Laboratory studies on arrival (day 8 of illness) demon-
strated leukocytosis (white blood count, 24 × 103/μL, normal
range 4-15 × 103/μL), thrombocytopenia (platelet count, 38
× 103/μL, normal range 150-450 × 103/μL), low fibrinogen
(104mg/dL, normal range 170-399mg/dL), hyponatremia
(132mmol/L, normal range 135-155mmol/L), and elevated
transaminases (alanine aminotransferase (ALT) 61U/L;
aspartate amino transferase (AST) 141U/L). A head CT scan
without contrast on arrival demonstrated no acute intracra-
nial abnormalities. A sepsis workup was performed, and the
patient was started on ceftriaxone, vancomycin, acyclovir,
and doxycycline. A lumbar puncture performed after platelet
transfusion (day 9 of illness) demonstrated clear fluid, total
nucleated cells of 7/μL (normal range 0-7 cells/μL), a glucose
of 75mg/dL (normal range 45-75mg/dL), and elevated
protein at 389mg/dL (normal range 15-40mg/dL). A broad
workup for infectious pathogens was sent, including for
tick-borne diseases.
Several hours after lumbar puncture, the patient became
hyperreflexic, with extensor posturing of all extremities in
response to noxious stimulation. A video EEG demonstrated
Periodic Lateralized Epileptiform Discharges (PLEDs). The
patient was treated with levetiracetam. MRI of the brain
revealed diffuse abnormal leptomeningeal enhancement with
numerous focal areas of restricted diffusion scattered
throughout the gray and white matter of both cerebral hemi-
spheres (Figure 2). A few hours later, her pupils were fixed
and dilated, and her EEG demonstrated diffuse attenuation
of all activity. Hyperosmolar therapy was administered. An
emergent noncontrasted head CT scan demonstrated diffuse
cerebral edema and diminished gray-white matter differenti-
ation with impending herniation of the cerebellar tonsils
through the foramen magnum. After an examination consis-
tent with brain death, followed by a cerebral brain flow study
that also showed no intracranial blood flow, support was
withdrawn prior to her second brain death exam based on
her family’s wishes.
High quantities of R. rickettsii DNA on peripheral
blood real-time PCR were reported 8 days after the study
was obtained on the ninth day of illness. A positive IgM
titer (1 : 64, normal range < 1 : 64) and undetectable IgG
titer for R. rickettsii were reported 6 days after the studies
were obtained.
3. Discussion
Rocky Mountain spotted fever (RMSF), if treated late in the
illness, can lead to potentially fatal complications such as
development of severe cerebral edema [3]. For this reason,
early treatment is essential. However, early diagnosis can be
difficult, particularly in areas where RMSF is not common.
Reviewing the case and the literature, we propose potential
clues from the history, physical exam, and lab findings that
may be useful in identifying higher risk cases that deserve
early intervention or close follow-up.
The incidence of spotted fever rickettsiosis (including
RMSF) has increased during the last decade, from less than
2 cases per million persons in 2000 to over 11 cases per mil-
lion persons in 2014 [4]. Illness occurs most frequently in the
summer months and six states (Tennessee, Delaware, Mis-
souri, Arkansas, North Carolina, and Oklahoma) account
for >60% of cases. Indiana had only 30 cases in 2015 [5], so
many providers in the state are not familiar with the illness.
The diagnosis of RMSF can be challenging even in areas with
more frequent RMSF, as the clinical presentation can resem-
ble that of many other infectious and noninfectious condi-
tions [6, 7].
Since fever and rash are among the most common rea-
sons that parents seek medical attention for their child [8]
and overtreatment of these children with doxycycline for sus-
pected RMSF is undesirable, when should one evaluate and
treat for RMSF in a child with fever and a rash? While there
are no absolute answers, some clinical clues may increase sus-
picion of RMSF and prompt early empiric treatment. Clues
from patient history that may increase suspicion of RMSF
include a travel history of camping in wooded areas. How-
ever, since RMSF can occur even in urban areas [9], lack of
a camping or hiking history does not exclude the diagnosis.
Persistence of both fever and rash should also increase suspi-
cion of RMSF, as many viral- and bacterial-associated rashes
resolve over a few days, even when fevers persist. The presen-
tation of the rash, including a classic “outward to inward”
progression and the presence of the rash on palms and soles,
can further support the diagnosis. However, many patients
will not have the classic rash progression (e.g., the case patient
did not), and some patients have no rash at all. In addition,
other infections cancause rasheson thepalmsandsoles, so this
sign supports, but is not pathognomonic for RMSF. Common
laboratory findings in RMSF include hyponatremia, lympho-
penia, thrombocytopenia, coagulopathy, and transaminitis
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[10]. All of these findings were present in the case patient at
the time of hospitalization, but many occur only late in the
disease process, as they did in this patient. The caveats men-
tioned illustrate why early diagnosis of RMSF is often diffi-
cult. Prior case series and the findings in the present case
report suggest that findings which by themselves may be
unremarkable, e.g., a history of camping, elevation of trans-
aminases, and persistence of fevers and rash together for
more than 4 days, should in conjunction increase clinical sus-
picion for RMSF.
The differential for RMSF includes viral infections, such
as parvovirus B19, adenovirus, Epstein-Barr virus, and mea-
sles; other bacterial illnesses, including sepsis and toxic shock
syndrome; other tick-borne illnesses such as Ehrlichia and
Anaplasma infections; and noninfectious illnesses such as
Kawasaki disease and systemic juvenile idiopathic arthritis [11].
Routine diagnosis of RMSF is by indirect fluorescent
antibody (IFA) testing for IgM and IgG antibodies to Rick-
ettsia rickettsii. IgG and IgM antibodies generally rise con-
currently during acute illness. However, the first antibody
test during acute illness is often negative as insufficient time
has elapsed for patients to mount an antibody response.
Therefore, testing should be done both acutely and repeated
2 to 6 weeks later. A positive IgM titer is suggestive of acute
infection, but IgM titers can remain positive for months, so
an IgM titer alone may not establish the diagnosis in a
highly endemic area. Recent observations that immunologic
reactions can result in frequent false-positive IgM levels
(6/13, 46% of patients in one small case series) [12] have
led to reconsideration of IgM antibodies in the diagnosis
and public health reporting of RMSF. Due to this limita-
tion, IgM no longer contributes to the surveillance case
definition as per the 2020 Council State of Territorial
Epidemiologists (CTSE) guidelines. A fourfold or greater
increase in IgG titer 2-6 weeks after the first testing
confirms acute infection with Rickettsia rickettsii. Whole
blood or serum DNA PCR can confirm the diagnosis early
in disease, and PCR testing can also be done on biopsy or
autopsy specimens to confirm infection.
Diagnostic imaging is recommended if there is clinical
suspicion for central nervous system involvement. CT imag-
ing of the head is insensitive for early changes of meningoen-
cephalitis. CT imaging abnormalities become more apparent
as diffuse cerebral edema, infarcts, and associated mass effect
progress. As a result, a positive head CT may present too late
in the disease process to have a relevant clinical impact. MRI
imaging of the brain can better delineate early leptomenin-
geal inflammation and focal cerebral edema. Contrast-
enhanced T1-weighted fat saturated and contrast-enhanced
fluid attenuation inversion recovery (FLAIR) sequences fur-
ther improve sensitivity for leptomeningeal inflammation,
although findings of meningoencephalitis and infectious vas-
culitis can be nonspecific. Diffusion-weighted imaging can
provide a useful clue to the diagnosis, with multiple foci of
periventricular white matter diffusion restriction in a “starry
sky” pattern characteristic for RMSF [13]. This pattern is pre-
sumed to arise from perivenular inflammation resulting in
focal infarcts and has also been described with CNS viral
infections of the genus Henipavirus, a virus carried by bats
that is not endemic in the United States [13]. This “starry
sky” pattern of white matter diffusion restriction can help
distinguish RMSF from other CNS diseases with perivenular
inflammation and deposition [13]. Along with the appropri-
ate clinical history, distinctively abnormal MRI findings can
help guide early antibiotic intervention.
Empiric treatment with doxycycline, the first-line ther-
apy for RMSF [6, 14], should begin immediately if RMSF is
suspected, as the results of definitive laboratory tests includ-
ing titers and PCR testing may take several days to return and
will not be available in time to inform the treatment decision.
Provision of doxycycline within 5 days of symptom onset is
critical: in one RMSF case series, mortality increased from
6.5% when doxycycline was given within 5 days to 22.9%
when given later than 5 days [15], and mortality as low as
(a) (b)
Figure 1: (a) The patient presented with a diffuse, nonblanching maculopapular rash with scattered petechiae and purpura involving the
trunk, upper and lower extremities, palms, and soles. (b) Area of petechiae on the arm where a blood pressure cuff was used.
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0.5% has been reported with treatment in a timely manner
[16]. Doxycycline treatment is sometimes delayed due to
concerns about the risk of dental staining. However, recent
studies have documented no dental staining or enamel hypo-
plasia following short courses of doxycycline, even after mul-
tiple courses were competed [17].
In summary, providers should have a low threshold of
suspicion for the diagnosis of RMSF in a child with mul-
tiple RMSF risk factors such as a travel history to tick-
infested areas, persistence of both fever and rash, specific
rash characteristics, and specific lab abnormalities (leuko-
penia/lymphopenia, thrombocytopenia, hyponatremia, and
elevation in transaminases). A child with multiple risk
factors, even in nonendemic areas, should receive early
empiric doxycycline treatment to prevent severe morbidity
and mortality.
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